Get started
Author

Karin Wåhlander

Observed names: K WAHLANDER, K. F.C. Wahlander, K. Wahlander, K. Wåhlander, Karin Wahlander, Karin Wåhlander, Wahlander, K, Wahlander, Karin, Wåhlander, K
Observed institutions: Northwestern University, Uppsala University, Karolinska University Hospital, Duke University, Novo Nordisk (Denmark), Sahlgrenska University Hospital, Karolinska Institutet, Duke Medical Center, AstraZeneca (Sweden), Imperial College London, University of Gothenburg
OpenAlex ID: A5024471893
Secondary Prevention of Venous Thromboembolism with the Oral Direct Thrombin Inhibitor Ximelagatran
2003 · Sam Schulman, Karin Wåhlander, et al. · New England Journal of Medicine · 448
PDF
Increased Activity of L-Type Ca 2+ Channels Exposed to Serum from Patients with Type I Diabetes
1993 · Lisa Juntti-Berggren, Olof Larsson, et al. · Science · 185
A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I
2003 · H. Eriksson, K. Wåhlander, et al. · Journal of Thrombosis and Haemostasis · 163
Activation by adrenaline of a low-conductance G protein-dependent K+ channel in mouse pancreatic B cells
1991 · Patrik Rorsman, Krister Bokvist, et al. · Nature · 135
Trousseau’s syndrome – what is the evidence?
2006 · David Bergqvist, Karin Wåhlander, et al. · Thrombosis and Haemostasis · 99
Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists
2009 · G. Y.H. Lip, L. H. Rasmussen, et al. · European Heart Journal · 94
PDF
Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers
2004 · Marcel Levi, Troy Sarich, et al. · Thrombosis and Haemostasis · 90
Factor V Leiden (G1691A) and Prothrombin Gene G20210A Mutations as Potential Risk Factors for Venous Thromboembolism after Total Hip or Total Knee Replacement Surgery
2002 · G. Larson, T. L. Lindahl, et al. · Thrombosis and Haemostasis · 89
Glucose-stimulated Insulin Biosynthesis Depends on Insulin-stimulated Insulin Gene Transcription
2000 · Barbara Leibiger, Karin Wåhlander, et al. · Journal of Biological Chemistry · 82
Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis
2002 · Karin Wåhlander, Leif Lapidus, et al. · Thrombosis Research · 67
Developing New Treatments for Heart Failure
2016 · Mihai Gheorghiade, Christopher J. Larson, et al. · Circulation Heart Failure · 63
PDF
Safety and tolerability of an immediate-release formulation of the oral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation
2010 · Lars Rasmussen, Arnljot Tveit, et al. · Thrombosis and Haemostasis · 52
Insulin resistance, endothelial function, angiogenic factors and clinical outcome in non-diabetic patients with chest pain without myocardial perfusion defects
2016 · Helena U. Westergren, Sara Svedlund, et al. · Cardiovascular Diabetology · 39
PDF
Effect of Melagatran on Prothrombin Time Assays Depends on the Sensitivity of the Thromboplastin and the Final Dilution of the Plasma Sample
2001 · Angela Menschiek-Lundin, Karin Wåhlander, et al. · Thrombosis and Haemostasis · 36
A review of the effects of the oral direct thrombin inhibitor ximelagatran on coagulation assays
2004 · Stefan C. Carlsson, Christer Mattsson, et al. · Thrombosis Research · 32
Acute antithrombotic effects of ximelagatran, an oral direct thrombin inhibitor, and r-hirudin in a human ex vivo model of arterial thrombosis
2003 · T.C. Sarich, J.I. Osende, et al. · Journal of Thrombosis and Haemostasis · 30
PDF
Pharmacokinetics of ximelagatran and relationship to clinical response in acute deep vein thrombosis
2005 · M CULLBERG, U ERIKSSON, et al. · Clinical Pharmacology & Therapeutics · 29
Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: A Phase II study of AZD0837 in patients who are appropriate for but unable or unwilling to take vitamin K antagonist therapy
2010 · Gregory Y.H. Lip, Lars H. Rasmussen, et al. · Thrombosis Research · 27
Alpha2-adrenoreceptor stimulation does not inhibit L-type calcium channels in mouse pancreatic β-cells
1991 · Krister Bokvist, Carina Ämmälä, et al. · Bioscience Reports · 25
Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatran
2005 · Torbjörn Lundström, Karin Wåhlander, et al. · Thrombosis and Haemostasis · 24
Fibrinolysis inhibitors in plaque stability: a morphological association of PAI‐1 and TAFI in advanced carotid plaque
2017 · A.‐C. Jönsson Rylander, A. Lindgren, et al. · Journal of Thrombosis and Haemostasis · 21
PDF
Histone deacetylase inhibitors stimulate tissue-type plasminogen activator production in vascular endothelial cells
2012 · Pia Larsson, Niklas Bergh, et al. · Journal of Thrombosis and Thrombolysis · 18
Risk of recurrent venous thromboembolism or bleeding in relation to thrombophilic risk factors in patients receiving ximelagatran or placebo for long‐term secondary prevention of venous thromboembolism
2006 · Karin Wåhlander, Henry Eriksson, et al. · British Journal of Haematology · 18
Effects of the Oral Direct Thrombin Inhibitor Ximelagatran on P-Selectin Expression and Thrombin Generation in Atrial Fibrillation
2003 · Michael Wolzt, Stig L. Boström, et al. · Pathophysiology of Haemostasis and Thrombosis · 18
Antithrombotic effects of ximelagatran plus acetylsalicylic acid (ASA) and clopidogrel plus ASA in a human ex vivo arterial thrombosis model
2006 · Maria Eriksson-Lepkowska, Per Nyström, et al. · Thrombosis and Haemostasis · 17
Works count: 48
Citation count: 1,991
H-index: 21
I10-index: 29
Year
Topic
Type